LPAR1 and psoriasis: In particular, a selective antagonist of LPA1 is under several clinical trials for the treatment of lung fibrosis (ClinicalTrials.gov ID: NCT01766817) and psoriasis (ClinicalTrials.gov ID: NCT02763969) [4].